Menu
← Oncology Approval Tracker
FDA DECISION ·
Enhertu
fam-trastuzumab deruxtecan-nxki · Daiichi Sankyo
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with HER2-positive gastric or gastroesophageal junction adenocarcinoma that is locally advanced or metastatic, after a trastuzumab-based regimen.
LAMPGEN ANALYSIS
Why it matters
The approval brings a HER2-directed antibody-drug conjugate into previously treated gastric and gastroesophageal junction cancer.
What research teams should watch
Document the gastric-specific HER2 result and earlier trastuzumab exposure, and plan pulmonary adverse event follow-up.
PRIMARY RECORDS